Evidence map›Paper›PMID 36359007›Full record

ArticleBiomolecules2022

LC-MS/MS Isomeric Profiling of

Cristian D Gutierrez Reyes, Md Abdul Hakim, Mojgan Atashi, Mona Goli, Sakshi Gautam, Junyao Wang, Andrew I Bennett, Jianhui Zhu, David M Lubman, Yehia Mechref

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. PredictiveACS omega · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. SerumJournal of proteome research · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. SerumBiomolecules · 2024
    Article
  15. Article
  16. SerumACS omega · 2024
    Article
  17. Multi Omics Applications in Biological Systems.Current issues in molecular biology · 2024
    Review
  18. Article
  19. Article
  20. Targeted Glycoproteomics Analysis Using MRM/PRM Approaches.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Cristian D Gutierrez ReyesDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0001-5229-4723
Md Abdul HakimDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Mojgan AtashiDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Mona GoliDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Sakshi GautamDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0001-8063-7391
Junyao WangDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0002-7614-5615
Andrew I BennettDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Jianhui ZhuDepartment of Surgery, The University of Michigan, Ann Arbor, MI 48109, USA.
David M LubmanDepartment of Surgery, The University of Michigan, Ann Arbor, MI 48109, USA.
Yehia MechrefDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0002-6661-6073
Texas Tech University · USUniversity of Michigan · US

Funding

Supplemental for Detection of Glycopeptides of MCI in Patient SerumR01CA160254 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David M. Lubman · 2012 to 2026
$5.4M
Sensitive and Quantitative MS-bases Glycomic Mapping PlatformR01GM112490 · NIGMS · TEXAS TECH UNIVERSITY · PI MECHREF, YEHIA · 2014 to 2024
$3.2M
Quantitative Characterization of Glycopeptide IsomersR01GM130091 · NIGMS · TEXAS TECH UNIVERSITY · PI Yehia Mechref · 2019 to 2026
$2.5M
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of DiseaseU01CA225753 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M., MECHREF, YEHIA · 2018 to 2021
$2.0M
Discovery and Validation of Biomarkers for Early Cancer Detection Using Mass SpectrometryR50CA221808 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHU, JIANHUI · 2018 to 2020
$189k
NCI NIH HHS 3R01CA160254NCI NIH HHS 3R01CA160254-S1NCI NIH HHS R01 CA160254NCI NIH HHS R50CA221808NCI NIH HHS U01 CA225753NCI NIH HHS U01CA225753NIGMS NIH HHS R01 GM130091NIH HHS 1R01GM112490-08
6 · The paper itself

Abstract

Mild cognitive impairment (MCI) is an early stage of memory loss that affects cognitive abilities, such as language or virtual/spatial comprehension. This cognitive decline is mostly observed with the aging of individuals. Recently, MCI has been considered as a prodromal phase of Alzheimer's disease (AD), with a 10-15% conversion rate. However, the existing diagnostic methods fail to provide precise and well-timed diagnoses, and the pathophysiology of MCI is not fully understood. Alterations of serum

Indexed as

Cognitive DysfunctionSerumBiomarkersChromatography, LiquidGlycoproteinsHumansPolysaccharidesTandem Mass SpectrometryBiomarkersGlycoproteinsPolysaccharidesbiomarker glycanisomeric N-glycansMCIneurological disorder

Identifiers

PMID36359007
PMCPMC9687829
OpenAlexW4308580463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.